Quantcast

European Commission Approves Expanded Use of Janssen’s STELARA for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.

Read more

Janssen nets FDA’s Breakthrough Therapy Designation for investigational prophylactic vaccine for the prevention of respiratory syncytial virus in older adults

The Janssen Pharmaceutical Companies of Johnson & Johnson got the FDA’s Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of #respiratory syncytial virus (RSV)- mediated lower respiratory tract disease in adults aged 60 years or older. @JNJNews

Read more